Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Clinical Study of Xingbaiji Formula in Combination with Chemotherapy and Sintilimab As First-Line Treatment for Metastatic Multi-Target Mutation-Negative Non-Small Cell Lung Cancer

NCT06848426 is registered in ClinicalTrials.gov with Jiangxi Provincial People's Hopital as lead sponsor.

NCT NCT06848426
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06848426 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Clinical Study of Xingbaiji Formula in Combination with Chemotherapy and Sintilimab As First-Line Treatment for Metastatic Multi-Target Mutation-Negative Non-Small Cell Lung Cancer
Lead sponsor
Jiangxi Provincial People's Hopital
Phase
Not applicable
Overall status
Not yet recruiting
Start date
March 10, 2025
Completion date
January 31, 2028
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer, non-small cell lung cancer metastatic, non-small cell lung cancer recurrent, non-small cell lung cancer stage iiib, non-small cell lung cancer stage iv